Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11
Yuichi Ishikawa(Nagoya University), Hitoshi Kiyoi(Nagoya University), Shigeki Ohtake(Kanazawa University), Toru Sakura(Gunma Saiseikai Maebashi Hospital), Noboru Asada(The University of Tokyo), Daiki Hirano(National Hospital Organization), Toru Kiguchi(Chugoku Central Hospital), Noriko Doki(Tokyo Metropolitan Komagome Hospital), Akihiro Tomita(Nagoya University), Kazuto Togitani(Kochi Medical School Hospital), Itaru Matsumura(Kindai University), Maki Hagihara(Yokohama City University Hospital), Yoshiko Atsuta(Aichi Medical University), Yukiyoshi Moriuchi(Sasebo City General Hospital), Naomi Kawashima(Nagoya University), Yasuhisa Yokoyama(University of Tsukuba), Heiwa Kanamori(Kanagawa Prefectural Hospital Organization), Tatsuki Tomikawa(Social Insurance Saitama Chuo Hospital), Nobuaki Dobashi(Jikei University School of Medicine), Yasushi Miyazaki(Nagasaki University), Shiro Koh(Fuchu Hospital), Hisayuki Yokoyama(Sendai Medical Center), Noriyoshi Iriyama(Nihon University), Masashi Sawa(Anjo Kosei Hospital), Akio Kohno(Konan Kosei Hospital), Norio Asou(Saitama Medical University), Tomoki Naoe(National Hospital Organization), Isamu Sugiura(Toyohashi Municipal Hospital)
Cited by 127
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3k